Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5882968 | Clinical Lymphoma Myeloma and Leukemia | 2014 | 6 Pages |
Abstract
VSLI plus rituximab resulted in durable responses in patients with heavily pretreated advanced stage DLBCL and MCL. The toxicity profile was predictable and manageable with limited hematologic toxicity. Despite near-universal previous VCR exposure (96%) and doses of VSLI unachievable with standard VCR treatment, peripheral neuropathy and constipation were modest. This study supports further evaluation of VSLI as a component of DLBCL management.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Lawrence D. Kaplan, Steven R. Deitcher, Jeffrey A. Silverman, Gareth Morgan,